Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: A randomized double-blind trial (NORA)

Tropical Medicine and International Health

Volumn 13, Issue 1, 2008, Pages 6-16

  Walker, A Sarah ^a,e   Mugyenyi, P ^b,c   Kityo, C ^b   Ssali, F ^b,c   Tumukunde, D ^b   Otim, T ^b   Namale, L ^b   Mukose, A ^b   Muhwezi, A ^b   Kabuye, G ^b   Mulindwa, G ^b   Atwine, D ^b   Kyomugisha, H ^b   Drasiku, A ^b   Tumusiime, C ^b   Sabiiti, J ^b   Zawedde, C ^b   Komugyena, J ^b   Okiror, J ^b   Byaruhanga, R ^b   Ocitti, P ^b   Bakainyaga Grace, T ^b   Katabira, H ^b   Barungi, G ^b   Masiira, D ^b   Atwine, A ^b   Murungi, S ^b   Tukamushaba, J ^b   Mugarura, L ^b   Mwesigwa, P ^b   Grosskurth, H ^a,c   Munderi, P ^a,c   Wangati, K ^a   Byomire, H ^a   Amuron, B ^a   Nsibambi, D ^a   Kasirye, R ^a   Zalwango, E ^a   Nakazibwe, M ^a   Kikaire, B ^a   Nassuna, G ^a   Massa, R ^a   Aber, M ^a   Namyalo, M ^a   Zalwango, A ^a   Generous, L ^a   Khauka, P ^a   Rutikarayo, N ^a   Nakahima, W ^a   Mugisha, A ^a   Nakiyingi Miiro, J ^a   Hughes, P ^a   Coutinho, A ^c   Etukoit, B ^c   Gilks, C ^c,d   Boocock, K ^d   Puddephatt, C ^d   Winogron, D ^c,d   Darbyshire, J ^c,e   Gibb, D M ^c,e   Burke, A ^e   Bray, D ^e   Babiker, A ^c,e   Wilkes, H ^e   Rauchenberger, M ^e   Sheehan, S ^e   Peto, L ^e   Taylor, K ^e   Weller, I ^c   Bahendeka, S ^c   Bassett, M ^c   Chogo Wapakhabulo, A ^c   Gazzard, B ^c   Hakim, J ^c   Latif, A ^c   Mugurungi, O ^c   Leith, J ^c   Loeliger, E ^c   Naidoo, P ^c   Palmer, M ^c   Rooney, J ^c   Steens, J M ^c   McLaren, A ^f   Hill, C ^f   Matenga, J ^f   Pozniak, A ^f   Serwadda, D ^f   Peto, T ^c   Palfreeman, A ^c   Borok, M ^c   Katabira, E ^c   Reid, A ^c   Bwakaga, H ^c   more..

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c MRC/UVRI Uganda Research Unit on AIDS ^*

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f Data and Safety Monitoring Committee

Author keywords

Africa; Antiretroviral therapy; HIV; Randomized controlled trial; Toxicity

Indexed keywords

ABACAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLACEBO;

COMPARATIVE STUDY; DISEASE TREATMENT; HEALTH AND SAFETY; HUMAN IMMUNODEFICIENCY VIRUS; TOXICITY;

ACUTE HEPATITIS; ADULT; ANEMIA; ARTICLE; BRAIN DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; FEMALE; FEVER; HEAD INJURY; HEMATEMESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPONATREMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NEUTROPENIA; PANCYTOPENIA; PARALYTIC ILEUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UGANDA; URTICARIA;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; UGANDA; ZIDOVUDINE;

EID: 39449098453     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2007.01973.x     Document Type: Article

References (17)

1. Bartlett JA asw@ctu.mrc.ac.uk, Fath MJ, Demasi R et al. (2006) An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 20, 2051 2064.
2. Brothers C, Cutrell A, Zhao H et al. (2005) Daily Administration of Abacavir is not a Clinical Risk Factor for Suspected Hypersensitivity Reactions in Clinical Trials and Rash Alone is not Sufficient to Diagnose the Reaction. 12th Conference on Retroviruses and Opportunistic Infections, Boston, Abstract 836.
3. Brothers C, Wannamaker P, Sutherland-Phillips D Hernandez J (2006) Lower Reported Rate of Suspected Hypersensitivity Reaction (HSR) to Abacavir (ABC) Among Black Patients. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract H-1065.
4. Division of AIDS (1992) Table for Grading Severity of Adult Adverse Experiences. National Institute of Allergy and Infectious Diseases, Bethesda.
5. Gilks CF, Crowley S, Ekpini R et al. (2006) The WHO public health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368, 505 510.
6. Gulick RM, Ribaudo HJ, Shikuma CM et al. for the AIDS Clinical Trials Group Study A5095 Team (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. The New England Journal of Medicine 350, 1850 1861.
7. Hughes AR, Mosteller M, Bansal AT et al. (2004) Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203 211.
8. Knobel H, Miro JM, Mahillo B et al. (2004) Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. Journal of Acquired Immune Deficiency Syndromes 37, 1276 1281.
9. van Leeuwen R, Katlama C, Murphy RL et al. (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17, 987 999.
10. van Leth F, Phanuphak P, Ruxrungtham K et al., for the 2NN Study team (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363, 1253 1263.
11. van Leth F, Andrews S, Grinsztejn B et al., for the 2NN study group (2005) The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 19, 463 471.
12. de Maat MM, ter Heine R, Mulder JW et al. (2003) Incidence and risk factors for nevirapine-associated rash. European Journal of Clinical Pharmacology 59, 457 462.
13. Martin A, Nolan D, Almeida CA, Rauch A Mallal S (2006) Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics 7, 15 23.
14. Montaner JS, Cahn P, Zala C et al., for the 1100.1286 Study Team (2003) Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. Journal of Acquired Immune Deficiency Syndromes 33, 41 46.
15. Reid A, Munderi P, Kityo C et al. (2004) A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa: the DART trial. 15th World AIDS Conference, Bangkok, Abstract TuPeB4495.
16. WHO (1990) Interim proposal for a WHO staging system for HIV infection and Disease. Weekly Epidemiological Record 65, 221 228.
17. WHO (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. WHO, Geneva.